US4900555A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Skin permeation enhancer compositions using sucrose esters
Assignee: Alza Corp
•
Filing: 1988-10-13
•
Granted: 1990-02-13
•
Expires: 2008-10-13
Abstract
Abstract A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with sucrose monolaurate or a mixture of sucrose esters of coconut fatty acids, which is predominatly sucrose monolaurate. Preferred embodiments of therapeutic systems for delivering the drug and the sucrose ester employ a matrix containing drug at a concentration above saturation.
Inventors
- 👤 Yu-Ling Cheng
- 👤 Robert M. Gale
- 👤 Edna Sugihara
- 👤 Harold F. Sanders
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 14:19
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K47/00; A61K47/06; A61K47/26; A61K9/7069; A61K9/7084
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
82 words
A device for the transdermal administration of a biologically active agent comprising, in combination: (a) a composition comprising a biologically active agent and a skin permeation enhancing amount of a material selected from the group consisting of sucrose monolaurate and mixtures of sucrose esters of coconut fatty acids which are predominantly sucrose monolaurate; (b) an occlusive backing behind the skin distal surface of said composition; and (c) means for maintaining said composition in agent and said material transferring relationship to intact skin.
Claim 2
Independent Claim
82 words
A device for the transdermal administration of a biologically active agent comprising, in combination: (a) a composition comprising a biologically active agent and a skin permeation enhancing amount of a material selected from the group consisting of sucrose monolaurate and mixtures of sucrose esters of coconut fatty acids which are predominantly sucrose monolaurate; (b) an occlusive backing behind the skin distal surface of said composition; and (c) means for maintaining said composition in agent and said material transferring relationship to intact skin.
Claim 3
Dependent Claim
13 words
The transdermal therapeutic system of claim 1 wherein said material is sucrose monolaurate.
Claim 4
Dependent Claim
25 words
The transdermal therapeutic system of claim 1 wherein said material is a mixture of sucrose esters of coconout fatty acids, which is predominantly sucrose monolaurate.
Claim 5
Dependent Claim
81 words
In a device for the transdermal administration of a biologically active agent comprising: (a) a source of a transdermally deliverable biologically active agent; (b) a source of a skin permeation enhancer for said agent; and (c) means for maintaining said system in agent and permeation enhancer transferring relationship to intact skin; the improvement wherein said permeation enhancer consists essentially of a material selected from the group consisting of sucrose monolaurate and mixtures of coconut fatty acids which are predominantly sucrose monolaurate.
Claim 6
Dependent Claim
81 words
In a device for the transdermal administration of a biologically active agent comprising: (a) a source of a transdermally deliverable biologically active agent; (b) a source of a skin permeation enhancer for said agent; and (c) means for maintaining said system in agent and permeation enhancer transferring relationship to intact skin; the improvement wherein said permeation enhancer consists essentially of a material selected from the group consisting of sucrose monolaurate and mixtures of coconut fatty acids which are predominantly sucrose monolaurate.
Claim 7
Dependent Claim
18 words
The system of claim 4 wherein said agent is present in said source at a concentration above saturation.
Claim 8
Dependent Claim
46 words
The system of claim 4 wherein said agent is present at a concentration sufficient to maintain the concentration above saturation for an extended period of time and said permeation enhancer is present at a concentration sufficient to provide permeation enhancement throughout said extended period of time.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-12 | 1993-08-14 | 1994-02-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-12 | 1997-08-14 | 1998-02-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-12 | 2001-08-14 | 2002-02-13 | $7700.00 | Window Closed / Lapsed |